Asian Stocks Rally as AI Boom and Iran Ceasefire Progress Lift Market Sentiment 
Dow Hits Record High as Healthcare and Consumer Stocks Lead Wall Street Rally 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Trump Administration Releases New UFO Files and Apollo Mission Records 
S&P 500, Nasdaq Hit Record Highs as Iran Ceasefire Talks and AI Rally Boost Markets 
Wall Street Hits New Highs as U.S.-Iran Ceasefire Talks Boost Market Sentiment 
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Asian Markets Slide as New U.S. Strikes on Iran Spark Investor Caution 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
New World Screwworm Found Near U.S. Border Raises Threat to Cattle Industry and Beef Prices 
Nikkei Hits Record High as AI Chip Stocks Power Japan Market Rally 
Keio University researchers have successfully transplanted into a patient with a severe spinal cord injury two million neural progenitor cells derived from other people’s iPS cells as part of a clinical study, offering hope for the paralyzed.
The patient is doing well.
Over the next year, while the patient undergoes rehabilitation, the team of doctors will see how safe and effective the treatment is.
The treatment is designed for patients with “complete paralysis” who are within two to four weeks of sustaining a spinal cord injury, called the subacute phase.
The iPS cells used were stockpiled by Kyoto University’s Center for iPS Cell Research and Application.
While rehabilitation is currently the only effective treatment for a spinal cord injury, the team believes that the transplanted cells could repair damaged neural circuits and create new tissue that can transmit signals from the brain.
The team plans to do the transplant into four more patients with spinal cord injuries.
While Japan’s Ministry of Health, Labor, and Welfare approved this clinical trial in February 2019, the process of finding suitable patients was postponed due to the COVID-19 pandemic.
